Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.

@article{LoRusso2013PhaseIS,
  title={Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.},
  author={Patricia M. LoRusso and Pasi Antero J{\"a}nne and Moacyr Ribeiro de Oliveira and Naiyer A Rizvi and Lisa M Malburg and Vicki Leigh Keedy and Lorrin K. Yee and Catherine Copigneaux and Thore Hettmann and Chi-Yuan Wu and Agnes Lee Ang and Abdel-Baset Halim and Robert A. Beckman and Darrin M. Beaupre and Jordan Berlin},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 11},
  pages={3078-87}
}
PURPOSE HER3 is a key dimerization partner for other HER family members, and its expression is associated with poor prognosis. This first-in-human study of U3-1287 (NCT00730470), a fully human anti-HER3 monoclonal antibody, evaluated its safety, tolerability, and pharmacokinetics in patients with advanced solid tumor. EXPERIMENTAL DESIGN The study was conducted in 2 parts: part 1--sequential cohorts received escalating doses (0.3-20 mg/kg) of U3-1287 every 2 weeks, starting 3 weeks after the… CONTINUE READING
35 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

U3–1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu model of human squamous cell carcinoma of the head and neck (SCCHN)

  • DJ Freeman, S Ogbagabriel, J Bready, J-K Sun, R Radisnky, T. Hettmann
  • Mol Cancer Ther
  • 2011
1 Excerpt

Identifying first in human (FIH) doses and schedule of U3-1287 (AMG 888), a fully human anti-HER3 mAb, based on preclinical pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data

  • P Lum, JJ Perez Ruixo, S Ogbagabriel, S Doshi, A Chen, BB Yang
  • Mol Cancer Ther
  • 2009

Fully human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo activities versus other HER family inhibitors in NSCLC models

  • M Treder, S Ogbagabriel, R Moor, U Schulze-Horsel, T Hettmann, M Rothe
  • Eur J Cancer
  • 2008

Similar Papers

Loading similar papers…